Therapeutical aspects of cerebrovascular disease

Eur Neurol. 1983:22 Suppl 1:74-7. doi: 10.1159/000115653.

Abstract

Treatment of hemorheologic alterations in patients with CVD must be directed to reduce enhanced platelet and red cell aggregation, to improve reduced red cell deformability, and to control plasmatic hypercoagulability.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Aspirin / therapeutic use
  • Blood Coagulation
  • Cerebrovascular Disorders / therapy*
  • Clofibrate / therapeutic use
  • Dipyridamole / therapeutic use
  • Erythrocyte Aggregation
  • Erythrocytes / drug effects
  • Erythrocytes / physiology
  • Humans
  • Ischemic Attack, Transient / prevention & control
  • Pentoxifylline / pharmacology
  • Pentoxifylline / therapeutic use
  • Plasma / physiology
  • Platelet Aggregation
  • Sulfinpyrazone / therapeutic use

Substances

  • Dipyridamole
  • Clofibrate
  • Aspirin
  • Pentoxifylline
  • Sulfinpyrazone